NEW YORK — German bioinformatics firm Noscendo has signed an agreement to collaborate with the University Hospital Bonn to characterize antibiotic-resistant pathogens using its Disqver next-generation sequencing-based diagnostic platform, the partners said on Monday.
Noscendo's Disqver is designed to analyze sequenced cell-free DNA from patient blood samples against a database of over 6,000 pathogens in order to detect bacteria, fungi, DNA viruses, and parasites, according to the company.